Date: 2017-03-21
Type of information: Development agreement
Compound: antibody against a novel target in the complement cascade with therapeutic potential in autoantibody- and complement-mediated indications including autoimmune haemolytic anaemia (AIHA) and antibody mediated rejection (AMR) following organ transplantation.
Company: Argen-X (Belgium - The Netherlands) Broteio Pharma (The Netherlands)
Therapeutic area: Autoimmune diseases
Type agreement: development
Action mechanism: monoclonal antibody
Disease: autoimmune haemolytic anaemia (AIHA), antibody mediated rejection (AMR) following organ transplantation.
Details: * On March 21, 2017, argenx announced that it has entered into a new collaboration with Broteio Pharma to develop an antibody against a novel target in the complement cascade with therapeutic potential in autoantibody- and complement-mediated indications including autoimmune haemolytic anaemia (AIHA) and antibody mediated rejection (AMR) following organ transplantation. The novel antibody targets a component of the complement cascade with therapeutic potential in both orphan and large market indications like Ischemia/Reperfusion Injuries. "This new therapeutic antibody has the potential to act alongside our lead product candidate ARGX-113 in a synergistic fashion. ARGX-113 targets FcRn in order to clear pathogenic IgG antibodies while our new complement-targeted antibody can also address IgM mediated autoimmune diseases," comments Tim Van Hauwermeiren, CEO of argenx. Under the terms of the agreement, argenx and Broteio will jointly develop the complement-targeted antibody to establish preclinical proof-of-concept using argenx's proprietary suite of technologies. Upon successful completion of these studies, argenx may exercise an exclusive option to license the program and assume responsibility for further development and commercialization.
Financial terms:
Latest news:
